透雲生物

Ty Biotech

Touyun Biotech Group Limited

透雲生物科技集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 1332)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Touyun Biotech Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") regarding the subscription of new shares under general mandate (the "**Subscription**") published on 25 August 2026 (the "**Subscription Announcement**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Subscription Announcement.

USE OF PROCEEDS

Upon Completion, the aggregate gross proceeds from the Subscription are expected to be approximately HK$15,006,000. The net proceeds from the Subscription are estimated to be approximately HK$14,990,000.

The Company wishes to clarify that the net proceeds of approximately HK$14,990,000 are intended to be fully utilised by 31 December 2026 and applied as follows:

1. HK$7,000,000 for capital injection into Ronghe Shidai (Chongqing) New Material Technology Co., Ltd.*, an indirect non-wholly-owned subsidiary of the Group principally engaged in the research and development, manufacturing and sales of high thermal conductivity new materials, for the construction of a new production line for such high thermal conductivity new materials in order to satisfy existing and future market orders;

2. HK$4,000,000 for repayment and settlement of the Group's outstanding payables; and

3. HK$3,990,000 for general working capital for daily operational expenses of the Group, including but not limited to staff costs and payroll, audit fees and other professional fees, and general office and operational expenses.

** For identification purpose only*

Save as disclosed above, all other information contained in the Subscription Announcement remains unchanged. The supplemental information set out in this announcement does not affect the other contents of the Subscription Announcement.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 31 August 2026

As at the date of this announcement, the Board comprises the following directors:

Executive Directors
Mr. Wang Liang *(Chairman)*
Ms. Zhou Ruijuan *(Vice chairlady)*
Mr. Du Dong

Non-executive Directors
Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors
Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen